GHRP-2

Overview

GHRP-2, also known as pralmorelin, is a synthetic growth hormone-releasing peptide that stimulates the body to secrete its own growth hormone (GH). It belongs to the same family of growth hormone secretagogues as GHRP-6 and hexarelin and works by mimicking the action of the natural hormone ghrelin. Among these peptides, GHRP-2 is notable because it has found a defined, if limited, medical role as a diagnostic agent.

In some countries, most notably Japan, pralmorelin has been used clinically as part of a test to assess growth hormone deficiency. In this diagnostic setting it is administered to provoke a measurable GH response, helping clinicians evaluate whether the pituitary gland is capable of secreting growth hormone normally. This is distinct from any therapeutic use to raise GH for treatment.

Outside of that diagnostic application, GHRP-2 is widely sold as a research chemical and marketed for muscle building and recovery without approval for such uses. It is also banned in competitive sport, reflecting its capacity to elevate growth hormone.

How it works

GHRP-2 acts on the growth hormone secretagogue receptor (GHS-R), the receptor for the natural hormone ghrelin. By binding and activating this receptor in the hypothalamus and pituitary gland, GHRP-2 prompts the pituitary to release a pulse of growth hormone. It does not introduce growth hormone from outside the body; instead, it stimulates the body's own secretory machinery, which is why it is classified as a secretagogue.

This pulsatile release of GH subsequently drives production of insulin-like growth factor 1 (IGF-1), the downstream mediator of many of growth hormone's effects on tissue. Because GHRP-2 works through the ghrelin pathway, it can also influence appetite, and it may modestly affect other ghrelin-related signals such as prolactin and cortisol.

The diagnostic use of GHRP-2 leverages this mechanism directly. By delivering a controlled stimulus to the pituitary and then measuring the resulting growth hormone in the blood, clinicians can determine whether the gland responds appropriately. A blunted response can support a diagnosis of growth hormone deficiency, while a robust rise indicates intact secretory capacity. The same provocative action that makes it useful diagnostically is what underlies its appeal and its prohibition in performance contexts.

Research & evidence

The strongest evidence base for GHRP-2 lies in its diagnostic application. Studies supporting its use as a growth hormone provocation test established that it reliably stimulates measurable GH secretion, which is the basis for its regulatory acceptance as pralmorelin in certain countries for evaluating growth hormone deficiency. This is a well-defined, narrow use grounded in its predictable pharmacology.

In contrast, evidence for the performance, muscle-building, and anti-aging uses commonly promoted online is weak. While short-term studies confirm that GHRP-2 raises growth hormone and IGF-1, there is a lack of large, controlled clinical trials demonstrating that this translates into meaningful, sustained improvements in body composition, strength, or health outcomes in healthy people. Much of the enthusiasm rests on extrapolation from acute hormonal effects rather than on robust outcome data.

As with other secretagogues, repeated stimulation can lead to a diminished response over time, and chronic dosing has not been validated for safety or benefit. The overall picture is of a compound with a legitimate but limited diagnostic role and an otherwise investigational status, where marketing claims considerably exceed the supporting clinical evidence.

Safety & legal status

GHRP-2's safety has been examined mainly in the context of single-dose diagnostic use, where it is generally well tolerated for that purpose. The safety of repeated or long-term administration, as occurs with non-medical use, is far less established. Potential effects include increased appetite, elevations in cortisol and prolactin, and changes in blood sugar and insulin sensitivity, given its action on the ghrelin receptor and its stimulation of growth hormone.

Because raising growth hormone and IGF-1 can theoretically promote tissue growth, unsupervised long-term use carries unquantified risks. Products sold as GHRP-2 outside of regulated diagnostic channels are research chemicals whose purity, sterility, and concentration are not guaranteed, introducing additional hazards of contamination and mislabeling.

From a legal and sporting standpoint, GHRP-2 is prohibited at all times under World Anti-Doping Agency rules as a growth hormone secretagogue, and athletes can face sanctions for its presence. While pralmorelin is approved for diagnostic use in some jurisdictions such as Japan, it is not approved as a therapeutic agent for muscle growth or anti-aging in major markets. Buyers of research-grade GHRP-2 should understand they are using an unapproved, unregulated substance.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Pralmorelin (GHRP-2): growth hormone-releasing peptide 2. Drugs R D. 2004. Peer-reviewed study
2. Okano M, Sato M, Kageyama S. Determination of pralmorelin (GHRP-2) and its metabolite in human urine by LC/ESI tandem mass spectrometry. Rapid Commun Mass Spectrom. 2010. Peer-reviewed study
3. Cox HD, Hughes CM, Eichner D. Detection of GHRP-2 and GHRP-6 in urine samples from athletes. Drug Test Anal. 2015. Peer-reviewed study
4. Yamamoto D, Ikeshita N, Matsubara T, et al. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008. Peer-reviewed study
5. Laferrère B, Abraham C, Russell CD, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005. Peer-reviewed study
6. Chen C, Farnworth P, Petersenn S, et al. Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells. Endocrine. 1998. Peer-reviewed study